Sugi Predict

Sugi Predict / Compounds / SCHEMBL1830243

SCHEMBL1830243

SCHEMBL1830243

C=CC(=O)C(=C)CCCCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.48
▸ CES2 O00748 4/20 0.46
▸ CES1 P23141 4/20 0.46
▸ AKR1B1 P15121 1/20 0.44
▸ TSHR P16473 5/20 0.44
▸ GPR84 Q9NQS5 7/20 0.43
▸ PPARG P37231 7/20 0.43
▸ PPARD Q03181 7/20 0.43
▸ PPARA Q07869 7/20 0.43
▸ HDAC11 Q96DB2 5/20 0.43
▸ PTPN1 P18031 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ TLR2 O60603 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ FABP4 P15090 2/20 0.43
▸ SLC22A6 Q4U2R8 1/20 0.43
▸ SLC22A8 Q8TCC7 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ESR1 P03372 1/20 0.43
▸ ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9501894 0.91 FAAH (0.42) FAAHCES2CES1AKR1B1TSHR
Acrylic Acid SCHEMBL5929266 0.79 ALOX15 (0.50) FAAHCES2CES1AKR1B1TSHR
Acrylic Acid SCHEMBL28906939 0.78 FNTA (0.48) CES2CES1AKR1B1TSHRGPR84
Acrylic Acid SCHEMBL8348271 0.78 FNTA (0.48) CES2CES1AKR1B1TSHRGPR84
Acrylic Acid SCHEMBL21808589 0.78 FNTA (0.48) CES2CES1AKR1B1TSHRGPR84
Acrylic Acid SCHEMBL812159 0.78 FNTA (0.48) CES2CES1AKR1B1TSHRGPR84
Acrylic Acid SCHEMBL9576580 0.78 FNTA (0.48) CES2CES1AKR1B1TSHRGPR84
Acrylic Acid SCHEMBL6067722 0.78 ALOX15 (0.48) FAAHCES2CES1AKR1B1TSHR
Acrylic Acid SCHEMBL15443369 0.78 FNTA (0.48) CES2CES1AKR1B1TSHRGPR84
Acrylic Acid SCHEMBL9640888 0.78 FNTA (0.48) CES2CES1AKR1B1TSHRGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3656756-B1 PROCESS FOR THE DIRECT ALPHA-METHYLENATION OF KETONES SPECIALTY OPERATIONS FRANCE (FR) 2025-12-03 — — EP disclosed
CN-113166027-B Direct alpha-methylation of ketones 罗地亚经营管理公司 2024-10-25 — — CN disclosed
US-11401228-B2 Process for the direct alpha-methylenation of ketones RHODIA OPERATIONS (FR) 2022-08-02 — — US disclosed
US-20220002221-A1 PROCESS FOR THE DIRECT ALPHA-METHYLENATION OF KETONES SPECIALTY OPERATIONS FRANCE (FR) 2022-01-06 — — US disclosed
CN-113166027-A Direct alpha-methylenation of ketones 罗地亚经营管理公司 2021-07-23 — — CN disclosed
EP-3656756-A1 PROCESS FOR THE DIRECT ALPHA-METHYLENATION OF KETONES RHODIA OPERATIONS (FR) 2020-05-27 — — EP disclosed
US-8324404-B2 3-thia-10-aza-phenanthrene derivatives NYCOMED GMBH (DE) 2012-12-04 — — US disclosed
EP-1797098-B1 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS NYCOMED GMBH (DE) 2011-05-04 — — EP disclosed
US-7838521-B2 3-oxa-10-aza-phenanthrenes NYCOMED GMBH (DE) 2010-11-23 — — US disclosed
US-20090239895-A1 Novel 3-thia-10-aza-phenanthrene derivatives NYCOMED GMBH (DE) 2009-09-24 — — US disclosed
US-7589205-B2 phosphodiesterase inhibitor; antiinflammatory agent; 3-thia-10-aza-phenanthrenes and iintermediates 3-(3,4-dialkoxy-phenyl)-tetrahydro-thiopyran-4-one and 3-(3,4-dialkoxy-phenyl)-1,1-dioxo-hexahydro-1-thiopyran-4-ylamine, useful for its preparation NYCOMED GMBH (DE) 2009-09-15 — — US disclosed
US-20080103168-A1 Novel 3-Thia-10-Aza-Phenanthrene Derivatives ATLANA PHARMA AG (DE) 2008-05-01 — — US disclosed
US-20070259868-A1 Novel 3-Oxa-10-Aza-Phenanthrenes ALTANA PHARMA AG (DE) 2007-11-08 — — US disclosed
EP-1797098-A2 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS Altana Pharma AG (DE) 2007-06-20 — — EP disclosed
EP-1791847-A2 NOVEL 3-THIA-10-AZA-PHENANTHRENE DERIVATIVES Altana Pharma AG (DE) 2007-06-06 — — EP disclosed
WO-2006027345-A2 NOVEL 3-THIA-10-AZA-PHENANTHRENE DERIVATIVES ALTANA PHARMA AG (DE) 2006-03-16 — — WO disclosed
WO-2006027344-A2 3-OXA-10-AZA-PHENANTHRENES AS PDE4 OR PDE3/4 INHIBITORS ALTANA PHARMA AG (DE) 2006-03-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103168-A1 Novel 3-Thia-10-Aza-Phenanthrene Derivatives PDE4A, PDE4B, PDE3A FAAH 3716/4885CES2 571/4885CES1 539/4885
US-20070259868-A1 Novel 3-Oxa-10-Aza-Phenanthrenes PDE4A, PDE4B, PDE3A FAAH 3587/4885CES2 835/4885CES1 718/4885
US-20090239895-A1 Novel 3-thia-10-aza-phenanthrene derivatives PDE4A, PDE4B, PDE3A FAAH 3716/4885CES2 571/4885CES1 539/4885
US-11401228-B2 Process for the direct alpha-methylenation of ketones ALKBH3, EHMT1, MGMT FAAH 198/4885CES2 913/4885CES1 368/4885
US-20220002221-A1 PROCESS FOR THE DIRECT ALPHA-METHYLENATION OF KETONES ALKBH3, EHMT1, MGMT FAAH 198/4885CES2 913/4885CES1 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.